Spots Global Cancer Trial Database for tarceva
Every month we try and update this database with for tarceva cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors | NCT00975182 | Non-Squamous No... | GDC-0941 erlotinib HCl | 18 Years - | Genentech, Inc. | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | NCT00130728 | Non-Small Cell ... | bevacizumab erlotinib HCl placebo | 18 Years - | Genentech, Inc. | |
| Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC) | NCT00419042 | Non Small Cell ... | TARCEVA Gemzar | 65 Years - | Groupe Francais De Pneumo-Cancerologie | |
| Ph I Dasatinib + Erlotinib in Recurrent MG | NCT00609999 | Glioblastoma Gliosarcoma | Erlotinib and D... | 18 Years - | Duke University | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | NCT00614653 | Pancreatic Canc... | Bevacizumab Erlotinib Capecitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) | NCT00257608 | Non-Small Cell ... | bevacizumab placebo erlotinib HCl | 18 Years - | Genentech, Inc. | |
| BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC | NCT00410059 | Lung Cancer | Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | NCT00769483 | Pancreatic Canc... Pancreatic Aden... | MK-0646 Gemcitabine Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer | NCT00243854 | Pancreatic Canc... | Tarceva | 18 Years - | Indiana University | |
| Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer | NCT00125359 | Carcinoma, Non-... | erlotinib and b... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | NCT00826449 | Lung Cancer Non-Small Cell ... | Dasatinib Erlotinib | 16 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | NCT00739063 | Breast Cancer | Tarceva | - | M.D. Anderson Cancer Center | |
| Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL) | NCT00391248 | Non-small Cell ... | Erlotinib | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | NCT00453362 | Non-Small Cell ... | 2-deoxy-2-[18F]... 3'-deoxy-3'-[18... erlotinib HCl | 18 Years - | Genentech, Inc. | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| Study of Erlotinib in Combination With Dasatinib | NCT00895128 | Advanced Cancer | Erlotinib Hydro... Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer | NCT00983307 | Carcinoma, Non-... | Erlotinib Hypofractionate... | 18 Years - | Thomas Jefferson University | |
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | NCT00522249 | Carcinoma, Rena... | Pegylated Alfa ... sunitinib erlotinib | 18 Years - | The Methodist Hospital Research Institute | |
| Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract | NCT01116622 | Advanced, Malig... | Bexarotene (Tar... Erlotinib (Tarc... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract | NCT01116622 | Advanced, Malig... | Bexarotene (Tar... Erlotinib (Tarc... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | NCT00137826 | Mesothelioma | Erlotinib Bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies | NCT01532011 | Advanced Cancer... Solid Tumors | Erlotinib Pralatrexate | 12 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | NCT00242502 | Hepatocellular ... Liver Cancer | Bevacizumab (Av... Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors | NCT00754104 | Solid Tumors | ABT-869 Tarceva | 18 Years - | Abbott | |
| Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors | NCT00754104 | Solid Tumors | ABT-869 Tarceva | 18 Years - | Abbott | |
| OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00036647 | Carcinoma, Non-... | Tarceva (erloti... | 18 Years - | Astellas Pharma Inc | |
| Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC | NCT00294762 | Carcinoma, Non-... | Tarceva carboplatin paclitaxel | 18 Years - | Astellas Pharma Inc | |
| Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | NCT01927744 | Head and Neck C... | Docetaxel Erlotinib Placebo Questionnaires Phone Call Chemotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | NCT00769483 | Pancreatic Canc... Pancreatic Aden... | MK-0646 Gemcitabine Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC) | NCT01026844 | Non-small Cell ... | erlotinib hydroxychloroqu... | 18 Years - | Massachusetts General Hospital | |
| A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | NCT02057380 | Advanced Solid ... | linsitinib erlotinib paclitaxel Bortezomib Dexamethasone | 18 Years - | Astellas Pharma Inc | |
| Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC) | NCT00419042 | Non Small Cell ... | TARCEVA Gemzar | 65 Years - | Groupe Francais De Pneumo-Cancerologie | |
| Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | NCT01192165 | Cancer | Trametinib (GSK... Docetaxel Erlotinib Pemetrexed Carboplatin nab-Paclitaxel Cisplatin | 18 Years - | GlaxoSmithKline | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | NCT01110876 | Brain Cancer Glioblastoma Mu... | Vorinostat Erlotinib Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer | NCT00140556 | Head and Neck C... Pharynx Cancer | Chemoradiothera... Cisplatin Bevacizumab Erlotinib | 18 Years - | Duke University | |
| Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | NCT00148772 | Prostate Cancer | Erlotinib (Tarc... | 18 Years - | NorthShore University HealthSystem | |
| BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00411632 | Lung Cancer | Bexarotene Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations | NCT00977470 | Non-small Cell ... | Erlotinib Hydroxychloroqu... | 18 Years - | Massachusetts General Hospital | |
| Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma | NCT00144976 | Head and Neck N... | Tarceva | 18 Years - | Institut Claudius Regaud | |
| Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin | NCT01059305 | Skin Cancer | Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer | NCT00125359 | Carcinoma, Non-... | erlotinib and b... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma | NCT00735306 | Pancreatic Canc... | Avastin Tarceva Radiation Thera... | 18 Years - | Duke University | |
| Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 | NCT00085839 | Non-Small Cell ... | Tarceva (Tradem... Combination car... | 18 Years - | Astellas Pharma Inc | |
| Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | NCT00671970 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | NCT00525525 | Glioblastoma Gliosarcoma | Bevacizumab Tarceva Temozolomide | 18 Years - | University of California, San Francisco | |
| Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers | NCT00832637 | Hepatocellular ... Cholangiocellul... Cholangiocarcin... Bile Duct Cance... Periampullary A... Gallbladder Can... Extrahepatic Bi... | Cisplatin Erlotinib Gemcitabine | 18 Years - | New Mexico Cancer Care Alliance | |
| Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | NCT00137826 | Mesothelioma | Erlotinib Bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | NCT00137839 | Adenocarcinoma Non-small Cell ... | Erlotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT00153803 | Carcinoma, Non-... Non-small Cell ... NSCLC | Erlotinib (tarc... Placebo | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Study of Ixazomib and Erlotinib in Solid Tumors | NCT02942095 | Solid Tumors | Ixazomib Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC | NCT00410059 | Lung Cancer | Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer | NCT00123851 | Colorectal Canc... Neoplasm Metast... | Tarceva (OSI-77... Capecitabine Oxaliplatin | 18 Years - | Dana-Farber Cancer Institute | |
| A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens | NCT00294736 | NSCLC | Tarceva | 18 Years - | Astellas Pharma Inc | |
| RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | NCT00843531 | Neuroendocrine ... | RAD001 erlotinib | 18 Years - | University of California, San Francisco | |
| OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer | NCT00076310 | Head and Neck C... | Docetaxel OSI-774 Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma | NCT02704767 | Lung Cancer | Apatinib Tarceva Placebo | 18 Years - 80 Years | First Affiliated Hospital of Kunming Medical University | |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies | NCT01532011 | Advanced Cancer... Solid Tumors | Erlotinib Pralatrexate | 12 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | NCT00137839 | Adenocarcinoma Non-small Cell ... | Erlotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 | NCT00085839 | Non-Small Cell ... | Tarceva (Tradem... Combination car... | 18 Years - | Astellas Pharma Inc | |
| Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | NCT00148772 | Prostate Cancer | Erlotinib (Tarc... | 18 Years - | NorthShore University HealthSystem | |
| A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib) | NCT00854308 | Non-Small Cell ... | Erlotinib HCl MetMAb placebo (0.9 % ... | 18 Years - | Genentech, Inc. | |
| Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | NCT00525525 | Glioblastoma Gliosarcoma | Bevacizumab Tarceva Temozolomide | 18 Years - | University of California, San Francisco | |
| Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer | NCT00707252 | Non-Small Cell ... | Polyphenon E Tarceva | 18 Years - | Louisiana State University Health Sciences Center Shreveport | |
| TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | NCT01455389 | Lung Cancer | DOTAP:Chol-TUSC... Erlotinib Dexamethasone Diphenhydramine | 18 Years - | Genprex, Inc. | |
| Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma | NCT00418327 | Malignant Brain... Brain Stem Glio... | Tarceva (Erloti... | 1 Year - 21 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | NCT01573702 | Non Small Cell ... | Stereotactic Ra... Erlotinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer | NCT00888511 | Non-small Cell ... | Tarceva Radiotherapy | 18 Years - 90 Years | Odense University Hospital | |
| The Role of Positron Emission Tomography (PET) During Erlotinib Treatment for Non-small Cell Lung Cancer | NCT01000428 | Erlotinib Lung Cancer | 18 Years - 85 Years | Asan Medical Center | ||
| TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | NCT01455389 | Lung Cancer | DOTAP:Chol-TUSC... Erlotinib Dexamethasone Diphenhydramine | 18 Years - | Genprex, Inc. | |
| A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | NCT00453362 | Non-Small Cell ... | 2-deoxy-2-[18F]... 3'-deoxy-3'-[18... erlotinib HCl | 18 Years - | Genentech, Inc. | |
| Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract | NCT01116622 | Advanced, Malig... | Bexarotene (Tar... Erlotinib (Tarc... | 18 Years - | Dartmouth-Hitchcock Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
